Multiple myeloma : New aspects of biology and treatment

Journal of Medical Investigation

Volumn 44, Issue 3-4, 1998, Pages 127-136

  Ozaki, Shuji ^a   Kosaka, Masaaki ^a  

^a UNIVERSITY OF TOKUSHIMA   (Japan)

Author keywords

Biology; Hematopoietic stem cell transplantation; Immunotherapy; Multiple myeloma; Treatment

Indexed keywords

GENETICS; HUMAN; MULTIPLE MYELOMA; PATHOPHYSIOLOGY; REVIEW;

HUMANS; MULTIPLE MYELOMA;

EID: 0031995304     PISSN: 13431420     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Article

References (98)

1. Riedel DA, Pottern LM:The epidemiology of multiple myeloma. Hematol Oncol Clin North Am 6 : 225-247, 1992
2. Togawa A, Amano M, Takaku F : The epidemiology of multiple myeloma in Japan. Japan Med J 3462 : 31-34, 1990 (in Japanese)
3. Gold JE, Schwam L, Castella A, Pike SB, Opfell R, Zalusky R : Malignant plasma cell tumors in human immunodeficiency virus-infected patients. Cancer 66 : 363-368, 1990
4. Kyle RA, Lust JA : Monoclonal gammopathies of undetermined significance. Semin Hematol 26 : 176-200, 1989
5. Kyle RA : Monoclonal gammopathy of undetermined significance and solitary plasmacytoma ; implications for progression to overt multiple myeloma. Hematol Oncol Clin North Am 11 : 71-87, 1997
6. Salmon SE, Seligmann M : B-cell neoplasia in man. Lancet 2 : 1230-1233, 1974
7. Hallek M, Bergsagel PL, Anderson KC : Multiple myeloma ; increasing evidence for a multistep transformation process. Blood 91 : 3-21, 1998
8. Kyle RA : Multiple myeloma ; review of 860 cases. Mayo Clin Proc 50 : 29-10, 1975
9. Alexanian R, Balcerzak S, Bonnet JD, Gehan EA, Haaut A, Hewlett JS, Monto RW : Prognostic factors in multiple myeloma. Cancer 36 : 1192-1201, 1975
10. Dune BGM, Salmon SE, Moon TE : Pretreatment tumor mass, cell kinetics, and prognosis in multiple myeloma. Blood 55 : 364-372, 1980
11. Durie BGM, Salmon SE : A clinical staging system for multiple myeloma ; correlation of measured myeloma cell mass with presenting clinical features, response to treatment, and survival. Cancer 36 : 842-854 ,1975
12. Cogne M, Silvain C, Khamlichi AA, Preud'homme JL : Structurally abnormal immunoglobulins in human immunoproliferative disorders. Blood 79 : 2181-2195, 1992
13. Klein B, Bataille R : Cytokine network in human multiple myeloma. Hematol Oncol Clin North Am 6 : 273-284, 1992
14. Harada H, Kawano MM, Huang N Harada Y, Iwato K, Tanabe O, Tanaka H, Sakai A, Asaoku H, Kuramoto A : Phenotypic difference of normal plasma cells from mature myeloma cells. Blood 81 : 2658-2663, 1993
15. Uchiyama H, Barut B, Chauhan D, Cannistra S, Anderson KC : Characterization of adhesion molecules on human myeloma cell lines. Blood 80 : 2306-2314, 1992
16. Teoh G, Anderson KC : Interaction of tumor and host cells with adhesion and extracellular matrix molecules in the development of multiple myeloma. Hematol Oncol Clin North Am 11 : 27-42, 1997
17. Drewinko B, Alexanian R, Boyer H, Barlogie B, Rubinow SI : The growth fraction of human myeloma cells. Blood 57 : 333-338, 1981
18. Latreille J, Barlogie B, Dosik G, Johnston DA, Drewiko B, Alexanian, R : Cellular DNA content as a marker of human multiple myeloma. Blood 55 : 403-408, 1980
19. Dewald GW, Kyle RA, Hicks GA, Greipp PR : The clinical significance of cytogenetic studies in 100 patients with multiple myeloma, plasma cell leukemia, or amyloidosis. Blood 66 : 380-390, 1985
20. Sawyer JR, Waldron JA, Jagannath S, Barlogie B : Cytogenetic findings in 200 patients with multiple myeloma. Cancer Genet Cytogenet 82 : 4149, 1995
21. Tricot G, Barlogie B, Jagannath S, Bracy D, Mattox S, Vesole DH, Naucke S, Sawyer JR : Poor prognosis in multiple myeloma is associated only with partial or complete deletions of chromosome 13 or abnormalities involving 11q and not with other karyotype abnormalities. Blood 86 : 4250-4256, 1995
22. Drach J, Angerler J, Schuster J, Rothermundt C, Thalhammer R, Haas OA, Jager U, Fiegl M, Geissler K, Ludwig H, Huber H : Interphase fluorescence in situ hybridization identifies chromosomal abnormalities in plasma cells from patients with monoclonal gammopathy of undetermined significance. Blood 86 : 3915-3921, 1995
23. Bakkus MHC, Heirman C, Van Riet I, Van Camp B, Thielemans K : Evidence that multiple myeloma Ig heavy chain VDJ genes contain somatic mutations but show no intraclonal variation. Blood 80 : 2326-2335, 1992
24. Ralph QM, Brisco MJ, Joshua DE, Brown R, Gibson J, Morley AA : Advancement of multiple myeloma from diagnosis through plateau phase to progression does not involve a new B-cell clone ; evidence from the Ig heavy chain gene. Blood 82 : 202-206, 1993
25. Takishita M, Kosaka M, Goto T, Saito S : Cellular origin and extent of clonal involvement in multiple myeloma ; genetic and phenotypic studies. Br J Haematol 87 : 735-742, 1994
26. Takishita M, Kosaka M : Multiple myeloma ; new evidence and insights from the immunoglobulin heavy chain gene and phenotypes. Leukemia and lymphoma 19 : 395-400, 1995
27. Witzig TE, Dhodapkar MV, Kyle RA, Greipp PR : Quantification of circulating peripheral blood plasma cells and their relationship to disease activity in patients with multiple myeloma. Cancer 72 : 108-113, 1993
28. Nishida K, Tamura A, Nakazawa N, Ueda Y, Abe T, Matsuda F, Kashima K, Taniwaki M : The Ig heavy chain gene is frequently involved in chromosomal translocations in multiple myeloma and plasma cell leukemia as detected by in situ hybridization. Blood 90 : 526-534, 1997
29. Greil R, Fasching B, Loidl P, Huber H : Expression of the c-myc proto-oncogene in multiple myeloma and chronic lymphocytic leukemia ; au in situ analysis. Blood 78 : 180-191, 1991
30. Chesi M, Bergsagel PL, Brents LA, Smith CA, Gerhard DS, Kuehl WM : Dysregulation of cyclin D1 by translocation into an IgH gamma switch region in two multiple myeloma cell lines. Blood 88 : 674-681, 1996
31. Chesi M, Nardini E, Brents LA, Schrock E, Ried T, Kuehl WM, Bergsagel PL : Frequent translocation t(4;14) (p16.3;q32.3) in multiple myeloma ; association with increased expression and activating mutations of fibroblast growth factor receptor 3.Nature Genet 16 : 260-264, 1997
32. Corradini P, Ladetto M, Voena C, Palumbo A, Inghirami G, Knowles DM, Boccadoro M, Pileri A : Mutational activation of N-and K-ras oncogenes in plasma cell dyscrasias. Blood 81 : 2708-2713, 993
33. Billadeau D, Jelinek DF, Shah N, LeBien TW, Van Ness B : Introduction of an activated N-ras oncogene alters the growth characteristics of the interleukin 6-dependent myeloma cell line ANBL6. Cancer Res 55 : 3640-3646, 1995
34. Liu P, Leong T, Quam L, Billladeau D, Kay NE, Greipp P, Kyle RA, Oken MM, Van-Ness B : Activating mutations of N-and K-ras in multiple myeloma show different clinical associations ; analysis of the Eastern Cooperative Oncology Group Phase III trial. Blood 88 : 2699-2706, 1996
35. Pettersson M, Jernberg-Wiklund H, Larsson LG, Sundstrom C, Givol I, Tsujimoto Y, Nilsson K : Expression of the bcl-2 gene in human multiple myeloma cell lines and normal plasma cells. Blood 79 : 495-502, 1992
36. Schwarze MM, Hawley RG : Prevention of myeloma cell apoptosis by ectopic bcl-2 expression or interleukin-6 madiated up-regulation of bcl-XL Cancer Res 55 : 2262-2265, 1995
37. Neri A, Baldini L, Trecca D, Cro L, Polli E, Maiolo A : p53 gene mutations in multiple myeloma are associated with advanced forms of malignancy. Blood 81 : 128-135, 1993
38. Corradini P, Inghirami G, Astolif M, Ladetto M, Voena C, Ballerini P, Gu W, Nilsson K, Knowles DM, Boccadoro M, Pileri A, Dalla-Favera R : Inactivation of tumor suppressor genes, p53 and Rb 1, in plasma cell dyscrasias. Leukemia 8 : 758-767, 1994
39. Juge-Morineau N, Mellerin MP, Francois S, Rapp MJ, Harousseau JL, Atniot M, Bataille R : High incidence of deletions but infrequent inactivation of the retinoblastoma gene in human myeloma cells. Br J Haemato 191 : 664-667, 1995
40. INK4c genes in multiple myeloma. Br J Haematol 96 : 98-102, 1997
41. Klein B : Cytokine, cytokine receptors, transduction signals and oncogenes in multiple myeloma. Semin Hematol 32 : 4-19, 1995
42. Kawano M, Hirano T, Matsuda T, Taga T, Horii Y, Iwato K, Asaoku H, Tang B, Tanabe O, Tanaka H, Kuramoto A, Kishimoto T: Autocrine generation and requirement of BSF-2/IL-6 for human multiple myelomas. Nature 332 : 83-85,1988
43. Klein B, Zhang XG, Jourdan M, Content J, Houssiau F, Aarden L, Piechaczyk M, Bataille R : Paracrine rather than autocrine regulation of myeloma-cell growth and differentiation by interleukin-6. Blood 73 : 517-526, 1989
44. Klein B, Wijdenes J, Zhang XG, Jourdan M, Boiron JM, Brochier J, Liautard J, Merlin M, Clement C, Morel-Fournier B, Lu ZY, Mannoni P, Sany J, Bataille R:M urine anti-interleukin-6monoclonal antibody therapy for a patient with plasma cell leukemia. Blood 78 : 1198-1204, 1991
45. Hardin J, MacLeod S, Grigorieva I, Chang R, Barlogie B, Xiao H, Epstein J : Interleukin-6 prevents dexamethasone-induced myeloma cell death. Blood 84 : 3063-3070, 1994
46. Bataille R, Chappard D, Klein B : Mechanisms of bone lesions in multiple myeloma. Hematol Oncol Clin North Am 6 : 285-295, 1992
47. Urashima M, Chauhan D, Uchiyama H, Freeman GJ, Anderson KC : CD40 ligand triggered interleukin-6 secretion in multiple myeloma. Blood 85 : 1903-1912, 1995
48. Urashima M, Ogata A, Chauhan D, Hatziyanni M, Vidriales MB, Dedera DA, Schlossman RL, Anderson KC : Transforming growth factor-β1 ; differential effects on multiple myeloma versus normal B cells. Blood 87 : 1928-1938, 1996
49. Rettig MB, Ma M, Pold M, Schiller G, Belson D, Savage A, Nishikubo C, Fraser J, Said JW, Berenson JR : KSHV infection of multiple myeloma bone marrow stroma. Science 276 : 1851-1854, 1997
50. Said JW, Rettig MR, Heppner K, Vesico RA, Schiller G, Ma IU, Belson D, Savage A, Shintaku IP, Koeffler HP, Asou H, Pinkus G, Pinkus J, Schrage M, Green E, Berenson JR : Localization of Kaposi's sarcoma-associated herpesvirus in bone marrow biopsy samples from patients with multiple myeloma. Blood 90 : 4278-4282, 1997
51. Gaillard JP, Bataille R, Brailly H, Zuber C, Yasukawa K, Attal M, Maruo N, Taga T, Kishimoto T, Klein B : Increased and highly stable levels of functional soluble interleukin-6 receptor in sera of patients with monoclonal gammopathy. Eur J Immunol 23 : 820-824, 1993
52. Jourdan M, Zhang XG, Portier M, Boiron JM, Bataille R, Klein B : IFN-alpha induced autocrine production of IL-6 in myeloma cell lines. J Immunol 147 : 4402-4407, 1991
53. Lu ZY, Zhang XG, Rodriguez C, Wijdenes J, Gu ZJ, Morel FB, Harousseau JL, Bataille R, Rossi JF, Klein B : Interleukin-10 is a proliferation factor but not a differentiation factor for human myeloma cells. Blood 85 : 2521-2527, 1995
54. Georgii-Hemming P, Wiklund HJ, Ljunggren O, Nilsson K : Insulin-like growth factor 1 is a growth and survival factor in human multiple myeloma cell lines. Blood 88 : 2250-2258, 1996
55. Ogata A, Chauhan D, Teoh G, Treon SP, Urashima M, Schlossman RL, Anderson KC : IL-6 triggers cell growth via the Ras-dependent mitogen-activated protein kinase cascade. J Immunol 159 : 2212-2221, 1997
56. Alexanian R, Dimopoulos M : The treatment of multiple myeloma. N Engl J Med 330 : 484-489, 1994
57. Alexanian R, Dimopoulos MA : Management of multiple myeloma. Semin Hematol 32 : 20-30, 1995
58. Salmon SE, Dalton WS, Grogan TM, Plezia P, Lehnert M, Roe DJ, Miller TP : Multidrug-resistant myeloma ; laboratory and clinical effects of verapamil as a chemosensitizer. Blood 78 : 44-50, 1991
59. Sonneveld P, Durie BG, Lokhorst HM, Marie JP, Solbu G, Suciu S, Zittoun R, Lowenberg B, Nooter K : Modulation of multidrug-resistant multiple myeloma by cyclosporin. Lancet 340 : 255-259, 1992
60. Grogan TM, Spier CM, Salmon SE, Matzner M, Rybsky J, Weinstein RS, Scheper RJ, Dalton WS : P-glycoprotein expression in human plasma cell myeloma ; correlation with prior chemotherapy. Blood 81 : 490-495, 1993
61. McElwain TJ, Powles RL : High dose intravenous mlphalan for plasma-cell leukemia and myeloma. Lancet 2 : 822-824, 1983
62. Barlogie B, Alexanian R, Smallwood L, Cheson B, Dixon D, Dicke K, Cabanillas F : Prognostic factors with high-dose melphalan for refractory multiple myeloma. Blood 72 : 2015-2019, 1988
63. Cunningham D, Paz-Ares L, Gore ME, Malpas J, Hickish T, Nicolson M, Meldrum M, Viner C, Milan S, Selby PJ, Norman A, Raymond J, Powles R: High-dose melphalan for multiple myeloma ; long-term follow-up data. J Clin Oncol 12 : 764-768, 1994
64. Barlogie B, Jagannath S, Dixon DO, Cheson B, Smallwood L, Hendrickson A, Purvis JD, Bonnem E, Alexanian R : High-dose melphalan and granulocyte-macrophage colony-stimulating factor for refractiry multiple myeloma. Blood 76 : 677-680, 1990
65. Barlogie B, Jagannath S, Vesole D, Tricot G : Autologous and allogeneic transplants for multiple myeloma. Semin Hematol 32 : 31-44, 1995
66. Gahrton G, Tura S, Ljungman P, Blade J, Brandt L, Cavo M, Facon T, Gratwohl A, Hagenbeek A, Jacobs P, de Laurenzi A, Lint MV, Michallet M, Nikoskelainen J, Reiffers J, Samson D, Verdonck L, de Witte T, Volin L : Prognostic factors in allogeneic bone marrow transplantation for multiple myeloma. J Clin Oncol 13 : 1312-1322, 1995
67. Tricot G, Vesole DH, Jagannath S, Hilton J, Munshi N, Barlogie B : Grafts-versus-myeloma effect ; proof of principle. Blood 87, 1196-1198, 1996
68. Anderson KC, Anderson J, Soiffer R, Freedman AS, Rabinowe SN, Robertson MJ, Spector N, Blake K, Murray C, Freeman A, Coral F, Marcus KC, Mauch P, Nadler LM, Ritz J : Monoclonal antibody-purged bone marrow transplantation therapy for multiple myeloma. Blood 82 : 2568-2576, 1993
69. Fermand JP, Chevret S, Ravaud P, Divine M, Leblond V, Dreyfus F, Mariette X, Brouet JC : High dose chemoradiotherapy and autologous blood stem cell transplantation in multiple myeloma ; results of a phase II trial involving 63 patients. Blood 82 : 2005-2009, 1993
70. Cunningham D, Paz-Ares L, Milan S, Powles R, Nicolson M, Hickish T, Selby P, Treleavan J, Viner C, Malpas J, Clevin M, Findlay M, Raymond J, Gore ME: High-dose melphalan and autologous bone marrow transplantation as consolidation in previously untreated myeloma. J Clin Oncol 12, 759-763, 1994
71. Harousseau JL, Attal M, Divine M, Milpied N, Marit G, Leblond V, Stoppa AM, Bourhis JH, Caillot D, Boasson M, Abgrall JF, Facon T, Colombat P, Cahn JY, Lamy T, Troussard X, Gratecos N, Pignon B, Auzanneau G : Comparison of autologous bone marrow transplantation and peripheral blood stem cell transplantation after first remission induction treatment in multiple myeloma. Bone Marrow Transplant 15 : 963-969, 1995
72. Attal M, Harousseau JL, Stoppa AM, Sotto JJ, Fuzibet JG, Rossi JF, Casassus P, Maisonneuve H, Facon T, Ifrah N, Payen C, Bataille R : A prospective, randomized trial of autologous bone marrow transplantation and chemotherapy in multiple myeloma. N Engl J Med 335 : 91-97, 1996
73. Bensinger WI, Rowley SD, Demirer T, Lilleby K, Schiffman K, Clift RA, Appelbaum FR, Fefer A, Barnett T, Storb R, Chauncey T, Mariarz RT, Klarnet J, McSweeney P, Holomberg L, Maloney DG, Weaver CH, Buckner CD : High-dose therapy followed by autologous hematopoietic stem-cell infusion for patients with multiple myeloma. J Clin Oncol 14 : 1447-1456, 1996
74. Marit G, Faberes C, Pico JL, Boiron JM, Bourhis JH, Brault P, Bernard P, Foures C, Cony-Makhoul P, Puntous M, Vezon G, Broustet A, Girault D, Reiffers J : Autologous peripheral-blood progenitor-cell support following high-dose chemotherapy or chemoradiotherapy in patients with high-risk multiple myeloma. J Clin Oncol 14 : 1306-1313, 1996
75. Vesole DH, Tricot G, Jagannath S, Desikan KR, Siegel D, Bracy D, Miller L, Cheson B, Crowley J, Barlogie B : Autotransplants in multiple myeloma ; what have we learned? Blood 88 : 838-847, 1996
76. Harousseau JL, Attal M: The role of autologous hematopoietic stem cell transplantation in multiple myeloma. Semin Hematol 34 : 61-66, 1997
77. Vesole DH, Barlogie B, Jagannath S, Cheson B, Tricot G, Alexanian R, Crowley J : High-dose therapy for refractory multiple myeloma ; improved prognosis with better supportive care and double transplants. Blood 84 : 950-956, 1994
78. Lemoli RM, Fortuna A, Motta MR, Rizzi S, Giudice V, Nannetti A, Martinelli G, Cavo M, Amabile M, Mangianti S, Fogli M, Conte R, Tura S : Concomitant mobilixation of plasma cells and hematopoietic progenitors into peripheral blood of multiple myeloma patients ; positive selection and transplantation of enriched CD34+ cells to remove circulating tumor cells. Blood 87 : 1625-1634, 1996
79. Reece DE, Barnett MJ, Connors JM, Klingemann HG, O'Reilly SE, Shepheld JD, Sutherland HJ Phillips GL : Treatment of multiple myeloma with intensive chemotherapy followed by autologous BMT using marrow purged with 4-hydroperoxycyclophosphamide. Bone Marrow Transplant 11 : 139-146, 1993
80. Schiller G, Vescio R, Freytes C, Spitzer G, Sahebi F, Lee M, Wu CH, Cao J, Lee JC, Hong CH, Lichtenstein A, Lill M, Hall J, Berenson R, Berenson J : Transplantation of CD34+ peripheral blood progenitor cells after high-dose chemotherapy for patients with advanced multiple myeloma. Blood 86 : 390-397, 1995
81. Gazitt Y, Reading CC, Hoffman R, Wickrema A, Vesole D, Jagannath S, Condino J, Lee B, Barlogie B, Tricot G : Purified CD34+ Lin-Thy+ stem cells do not contain clonal myeloma cells. Blood 86 : 381-389, 1995
82. Belch AR, Bergsagel DE, Wilson K, O'Reilly S, Wilson J, Sutton D, Pater J, Johnston D, Zee B : Effect of daily etidronate on the osteolysis of multiple myeloma. J Clin Oncol 9 : 1397-1402, 1991
83. Lahtinen R, Laakso M, Palva I, Virkkunen P, Elomaa I : Randomised, placebo-controlled multicentre trial of clodronate in multiple myeloma. Lancet 340 : 1049-1052, 1992
84. Berenson JR, Lichtenstein A, Porter L, Dimopoulos MA, Bordoni R, George S, Lipton A, Keller A, Ballester O, Kovacs MJ, Blacklock HA, Bell R, Simeone J, Reitsma DJ, Heffernan M, Seaman J, Knight RD : Efficacy of pamidronate in reducing skeletal events in patients with advanced multiple myeloma. N Engl J Med 334 : 488-493, 1996
85. Cazzola M, Messinger D, Battistel V, Bron D, Cimino R, Enller-Ziegler L, Essers U, Greil R, Grossi A, Jager G, LeMevel A, Najman A, Silingardi V, Spriano M, van Hoof A, Ehmer B : Recombinant human erythropoietin in the anemia associated with multiple myeloma or non-Hodgkin's lymphoma ; dose finding and identification of predictors of response. Blood 86 : 4446-4453, 1995
86. Osterborg A, Boogaerts MA, Cimino R, Essers U, Holowiecki J, Juliusson G, Jager G, Najman A, Peest D : Recombinant human erythropoietin in transfusion-dependent anemia patients with multiple myeloma and non-Hodgkin's lymphoma ; a randomised multicenter study. Blood 87 : 2675-2682, 1996
87. Stevenson FK, Bell AJ, Cusack R, Hamblin TJ, Slade CJ, Spellerberg MB, Stevenson GT : Preliminary studies for an immunotherapeutic approach to the treatment of human myeloma using chimeric anti-CD38 antibody. Blood 77 : 1071-1079, 1991
88. Goldmacher VS, Bourret LA, Levine BA, Rasmussen RA, Pourshadi M, Lambert JM Anderson KC: Anti-CD38-blocked ricin : An immunotoxin for the treatment of multiple myeloma. Blood 84 : 3017-3025, 1994
89. Ellis JH, Barber KA, Tutt A, Hale C, Lewis AP, Glennie MJ, Stevenson GT, Crowe JS : Engineered anti-CD38 monoclonal antibodies for immunotherapy of multiple myeloma. J Immunol 155 : 925-937, 1995
90. Huang YW, Richardson JA, Vitetta ES : Anti-CD54 (ICAM-1) has antitumor activity in SCID mice with human myeloma cells. Cancer Res 55 : 610-616, 1995
91. Hoover RG, Lary C, Page R, Travis P, Owens R, Flick J, Kornbluth J, Barlogie B : Autoregulatory circuits in myeloma;tumor cell cytotoxicity mediated by soluble CD16. J Clin Invest 95 : 241-247, 1995
92. Goto T, Kennel SJ, Abe M, Takishita M, Kosaka M, Solomon A, Saito S : A novel membrane antigen selectively expressed on terminally differentiated human B cells. Blood 84 : 1922-1930, 1994
93. Ozaki S, Kosaka M, Wakatsuki S, Abe M, Koishihara Y, Matsumoto T : Immunotherapy of multiple myeloma with a monoclonal antibody directed against a plasma cell-specific antigen, HM1.24. Blood 90 : 3179-3186, 1997
94. Bataille R, Barlogie B, Lu ZY, Rossi J-F, Lavabre-Bertrand T, Beck T, Wijdenes J, Brochier J, Klein B : Biologic effects of anti-interleukin-6 murine monoclonal antibody in advanced multiple myeloma. Blood 86 : 685-691, 1995
95. Harousseau JL : Therapeutic use of cytokines in human multiple myeloma. Cytokines in human multiple myeloma. R. G. Landes, Austin, 1994
96. Kwak LW, Taub DD, Duffey PL, Bensinger WI, Bryant EM, Reynolds CW, Longo DL: Transfer of myeloma idiotype-specific immunity from an actively immunised marrow donor. Lancet 345 : 1016-1020, 1995
97. Stevenson FK, Zhu D, King CA, Ashworth LJ, Kumar S, Thompsett A, Hawkins PE : A genetic approach to idiotypic vaccination for B cell lymphoma. Ann N Y Acad Sci 772 : 212-226, 1995
98. Yi Q, Osterborg A, Bergenbrant S, Mellstedt H, Holm G, Lefvert AK : Idiotype-reactive T-cell subsets and tumor load in monoclonal gammopathies. Blood 86 : 3043-3049, 1995